ME02100B - Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora - Google Patents

Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora

Info

Publication number
ME02100B
ME02100B MEP-2015-55A MEP5515A ME02100B ME 02100 B ME02100 B ME 02100B ME P5515 A MEP5515 A ME P5515A ME 02100 B ME02100 B ME 02100B
Authority
ME
Montenegro
Prior art keywords
pyrazol
pyrimidin
bromo
amine
disease
Prior art date
Application number
MEP-2015-55A
Other languages
English (en)
Inventor
Gómez Juan Alberto Camacho
Laria Julio Cesar Castro-Palomino
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Publication of ME02100B publication Critical patent/ME02100B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)

Claims (18)

1. Jedinjenje formule (I):gde- R1 predstavlja petočlani heteroaril prsten izabran od pirazol, tiazol, ili triazol prstenova po izboru supstituisanih sa jednim ili dva halogena atoma ili jednom ili dve metil ili trifluorometil grupe- R2 predstavlja vodonikov atom- R3 predstavlja atom broma, atom hlora ili cijano grupu- R4 predstavlja nezavisno:a) petočlanu heteroaril grupu po izboru supstituisanu jednim ili više halogenih atoma ili jednom ili više C1-C8 alkil, cikloalkil, C1-C8 alkoksi, C1-C8 alkiltio, amino, mono- ili di-C1-C8 alkilamino grupab) grupu -N(R5)(R6) u kojoj R5 i R6 predstavljaju nezavisno:- vodonikov atom- alkil ili cikloalkil grupu od 3 do 6 ugljenikovih atoma, linearnu ili razgranatu, po izboru supstituisanu sa jednim ili više halogenih atoma ili jednom ili više cikloalkil, hidroksi, C1-C8 alkoksi, amino, mono- ili di- C1-C8 alkilamino grupa- ili R5 i R6 formiraju zajedno sa azotovim atomom za koji su vezani zasićenu heterocikličnu grupu sa od 4 do 6 članova u koju dalje može biti uveden heteroatom, koji je po izboru supstituisan sa jednim ili više halogenih atoma ili jednom ili više C1-C8 alkil, hidroksi, C1-C8 alkoksi, amino, mono- ili di- C1-C8 alkilamino grupa,ilic) grupu -OR7 ili -SR7, gde R7 predstavlja nezavisno:- C1-C8 alkil ili cikloalkil grupu, linearnu ili razgranatu, po izboru supstituisanu sa jednim ili više halogenih atoma ili sa jednom ili više C1-C8 alkil, C1-C8 alkoksi, amino, mono- ili di- C1-C8 alkilamino grupa- Fenil prsten po izboru supstituisan sa jednim ili više halogenih atoma ili njihovom farmaceutski prihvatljivom soli
2. Jedinjenje prema patentnom zahtevu 1 u kome R4 predstavlja pirazolski prsten vezan na položaju 2 pirimidinskog prstena preko azotovog atoma pirazolskog prstena, gde je ovaj pirazolski prsten po izboru supstituisan sa jednim ili dva halogena atoma ili sa jednom ili dve metil grupe.
3. Jedinjenje prema patentnom zahtevu 1 u kome R4 predstavlja 2-tiazolil prsten, gde je ovaj tiazolski prsten po izboru supstituisan sa jednim ili dva halogena atoma ili sa jednom ili dve metil grupe.
4. Jedinjenje prema patentnom zahtevu 1 u kome R4 predstavlja grupu -N(R5)(R6) kao što je definisano u patentnom zahtevu 1.
5. Jedinjenje prema patentnom zahtevu 4 u kome R5 predstavlja vodonikov atom i R6 predstavlja alkil ili cikloalkil grupu sa 3 do 6 ugljenikovih atoma, linearnu ili razgranatu, po izboru supstituisanu sa halogenim atomima, amino, C1-C8 alkilamino.
6. Jedinjenje prema patentnom zahtevu 1 u kome R3 predstavlja atom broma ili hlora.
7. Jedinjenje prema patentnom zahtevu 6 u kome R1 predstavlja pirazolski ili tiazolski prsten od kojih su oba po izboru supstituisana sa jednim ili dva halogena atoma ili sa jednom ili dve metil ili trifluorometil grupe, i R4 predstavlja pirazolski ili tiazolski prsten od kojih su oba po izboru supstituisana sa jednim ili dva halogena atoma ili sa jednom ili dve metil grupe.
8. Jedinjenje prema patentnom zahtevu 6 u kome R1 predstavlja pirazolski prsten po izboru supstituisan sa jednim ili dva halogena atoma ili sa metil ili trifluorometil grupama, i R4 predstavlja pirazolski prsten po izboru supstituisan sa jednim ili dva halogena atoma ili sa metil grupama.
9. Jedinjenje prema patentnom zahtevu 6 u kome R1 predstavlja pirazol ili tiazol prstenove po izboru supstituisane sa jednim ili dva halogena atoma, metil ili trifluorometil grupama, i R4 predstavlja grupu -N(R5)(R6).
10. Jedinjenje prema patentnom zahtevu 6 u kome R1 predstavlja pirazol ili tiazol prstenove po izboru supstituisane sa jednim ili dva halogena atoma, metil ili trifluorometil grupama, i R4 predstavlja grupu SR7 ili OR7, gde R7 predstavlja linearnu ili razgranatu C1-C8 alkil grupu po izboru supstituisanu sa atomima fluora.
11. Jedinjenje prema patentnom zahtevu 1 koje je jedno od: 5-brom-2,6-di-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(4-metil-1H-pirazol-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(1H-pirazol-1-il)-6-(pirolidin-1-il)pirimidin-4-amina 5-brom-N4-ciklopentil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-6-(piperidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-morfolino-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(4-metilpiperazin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-ciklopropil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 6-(azetidin-1-il)-5-brom-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-ciklobutil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-6-(2-metilpirolidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-((R)-2-metilpirolidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 1-[6-amino-5-brom-2-(1H-pirazol-1-il)pirimidin-4-il]azetidin-3-ola 1-[6-amino-5-brom-2-(1H-pirazol-1-il)pirimidin-4-il]pirolidin-3-ola 5-brom-6-((S)-3-fluoropirolidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-[(S)-3-(dimetilamino)pirolidin-1-il]-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(2,5-dimetilpirolidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(3,3-difluoroazetidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-izopropil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-N4-propil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-hlor-2,6-di-(1H-pirazol-1-il)pirimidin-4-amina 4-amino-2,6-di-(1H-pirazol-1-il)pirimidin-5-karbonitrila 4-amino-6-N-ciklopentilamino-2-(1H-pirazol-1-il)pirimidin-5-karbonitrita N4-terc-butil-5-brom-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2-(4-metil-1H-pirazol-1-il)-6-(1H-pirazol-1-il)pirimidin-4-amina 6-(azetidin-1-il)-5-brom-2-(4-metil-1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-ciklopentil-2-(4-metil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-N4-ciklopropil-2-(4-metil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-N4-ciklobutil-2-(4-metil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2-(4-metil-1H-pirazol-1-il)-6-(2-metilpirolidin-1-il)pirimidin-4-amina 5-brom-2-(4-metil-1H-pirazol-1-il)-6-((R)-2-metilpirolidin-1-il)pirimidin-4-amina 5-brom-N-ciklopropil-2-(4-hlor-1H-pirazol-1-il)pirimidin-4,6-diamina 6-(azetidin-1-il)-5-brom-2-(4-hlor-1H-pirazol-1-il)pirimidin-4-amina 5-brom-2,6-di-(4-metil-1H-pirazol-1-il)pirimidin-4-amina 5-brom-2,6-di-(4-hlor-1H-pirazol-1-il)pirimidin-4-amina 5-brom-2,6-di-(3-metil-1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(3,5-dimetil-1H-pirazol-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(1H-imidazol-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(4-hlor-1H-pirazol-1-il)-2(1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(1H-pirazol-1-il)-6-(2H-1,2,3-triazol-2-il)pirimidin-4-amina 5-brom-2-(1H-pirazol-1-il)-6-(1H-1,2,4-triazol-1-il)pirimidin-4-amina 5-brom-6-izopropoksi-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(4-hlor-1H-pirazol-1-il)-6-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(4-hlor-1H-pirazol-1-il)-6-(4-metil-1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(3,5-dimetil-1H-pirazol-1-il)-6-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-ciklopentil-2-(3,5-dimetil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2-(3,5-dimetil-1H-pirazol-1-il)-6-(pirolidin-1-il)pirimidin-4-amina 5-brom-N4-izopropil-2-(3,5-dimetil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2,6-bis(3,5-dimetil-1H-pirazol-1-il)pirimidin-4-amina 5-Brom-2,6-di(tiazol-2-il)pirimidin-4-amina 5-Brom-2-(1H-pirazol-1-il)-6-(tiazol-2-il)pirimidin-4-amina 5-Brom-6-(1H-pirazol-1-il)-2-(tiazol-2-il)pirimidin-4-amina 5-brom-N4-[1-(dimetilamino)propan-2-il]-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-N4-(1-metoksipropan-2-il)-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-6-(1H-pirazol-1-il)-2-(2H-1,2,3-triazol-2-il)pirimidin-4-amina 5-brom-6-etoksi-2-(1H-pirazol-1-il)pirimidin-4-amina.
12. Jedinjenje prema bilo kojem od patentnih zahteva od 1 do 11 za primenu u lečenju patološkog stanja ili oboljenja koje je podložno ublaženju antagonizmom adenozinskog A2a receptora.
13. Jedinjenje prema patentnom zahtevu od 1 do 11 za primenu u lečenju patološkog stanja ili oboljenja gde je patološko stanje ili oboljenje ishemija, supraventrikularna aritmija, atrijalna fibrilacija, akutna bubrežna insuficijencija, miokardijalna reperfuziona povreda, oboljenja usled zadržavanja tečnosti, alergijske reakcije uključujući ali ne limitirajući se na rinitis, urtikariju, sklerodermu, artritis, druga autoimuna oboljenja, inflamatornu bolest creva, diabetes mellitus, gojaznost, Parkinsonovu bolest, Hantingtonovu bolest, distonije kao što su sindrom nemirnih nogu, diskinezije kao što su one izazvane produženom primenom dopamina ili neuroleptičkih lekova ili poremećajima spavanja, kongestivnom srčanom insuficijencijom, hipertenzijom, intradilatacijskom hipotenzijom, demencijom, anksioznim poremećajima i glaukomom.
14. Jedinjenje prema patentnom zahtevu 13 za primenu u lečenju patološkog stanja ili oboljenja gde su patološka stanja ili oboljenja aritmije, atrijalna fibrilacija, Parkinsonova bolest, Hantingtonova bolest, Alchajmerova bolest, distonije kao što su sindrom nemirnih nogu, diskinezije kao što su one izazvane produženom primenom dopamina ili neuroleptičkih lekova ili poremećajima spavanja, demencijom, anksioznim poremećajima i diabetes mellitus-om.
15. Farmaceutska kompozicija koja sadrži jedinjenje koje je definisano u bilo kom od patentnih zahteva od 1 do 11 pomešana sa farmaceutski prihvatljivim rastvaračem ili nosačem.
16. Kombinovani proizvod koji sadrži jedinjenje prema bilo kom od patentnih zahteva od 1 do 11 i još jedno jedinjenje za lečenje oboljenja kao što su ishemija, supraventrikularna aritmija, atrijalna fibrilacija, akutna bubrežna insuficijencija, miokardijalna reperfuziona povreda, oboljenja usled zadržavanja tečnosti, alergijske reakcije uključujući ali ne limitirajući se na rinitis, urtikariju, sklerodermu, artritis, druga autoimuna oboljenja, inflamatornu bolest creva, diabetes mellitus, gojaznost, Parkinsonovu bolest, Hantingtonovu bolest, Alchajmerovu bolest, distonije kao što su sindrom nemirnih nogu, diskinezije kao što su one izazvane produženom primenom dopamina ili neuroleptičkih lekova ili poremećajima spavanja, kongestivnom srčanom insuficijencijom, hipertenzijom, intradilatacijskom hipotenzijom, demencijom, anksioznim poremećajima i diabetes mellitus-om, za istovremenu, odvojenu ili sekvencijalnu primenu.
17. Kombinovani proizvod koji sadrži jedinjenje prema bilo kom od patentnih zahteva od 1 do 11 sa levodopom, agonistima dopamina, MAO-B inhibitorima, inhibitorima acetilholin esteraze ili bilo kojim lekom koji se koristi za lečenje Parkinsonove bolesti, Hantingtonove bolesti i Alchajmerove bolesti.
18. Kombinovani proizvod koji sadrži jedinjenje prema bilo kom od patentnih zahteva od 1 do 11 sa insulinom, metforminom, GLP-agonistima, sulfonilureama, DPP-IV inhibitorima ili bilo kojim lekom koji se koristi za lečenje dijabetesa.
MEP-2015-55A 2010-03-31 2011-03-29 Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora ME02100B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201030489A ES2365960B1 (es) 2010-03-31 2010-03-31 Nuevos antagonistas de los receptores de adenosina.
PCT/IB2011/000664 WO2011121418A1 (en) 2010-03-31 2011-03-29 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
EP11719879.6A EP2552909B1 (en) 2010-03-31 2011-03-29 4-aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
ME02100B true ME02100B (me) 2015-10-20

Family

ID=44120157

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-55A ME02100B (me) 2010-03-31 2011-03-29 Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora

Country Status (22)

Country Link
US (1) US8796284B2 (me)
EP (1) EP2552909B1 (me)
JP (1) JP5725383B2 (me)
KR (1) KR101441781B1 (me)
CN (1) CN102892761B (me)
AU (1) AU2011234144B2 (me)
BR (1) BR112012024870B1 (me)
CA (1) CA2795009C (me)
CY (1) CY1116328T1 (me)
DK (1) DK2552909T3 (me)
EA (1) EA021565B1 (me)
ES (2) ES2365960B1 (me)
HR (1) HRP20150366T1 (me)
ME (1) ME02100B (me)
MX (1) MX2012011240A (me)
PL (1) PL2552909T3 (me)
PT (1) PT2552909E (me)
RS (1) RS53939B1 (me)
SI (1) SI2552909T1 (me)
SM (1) SMT201500097B (me)
WO (1) WO2011121418A1 (me)
ZA (1) ZA201207259B (me)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
EA035349B1 (ru) 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
ES2480341B1 (es) * 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN103626741A (zh) * 2013-11-26 2014-03-12 苏州大学 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物
CN103664908A (zh) * 2013-12-10 2014-03-26 苏州大学 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
EP3324974B1 (en) 2015-07-24 2022-06-08 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods for treating diseases, and methods for preparing compounds
LT3334431T (lt) * 2015-08-11 2019-12-27 Novartis Ag 5-brom-2,6-di-(1h-pirazol-il)pirimidin-4-aminas, skirtas panaudoti vėžio gydymui
PH12018500284B1 (en) * 2015-08-11 2023-08-16 Novartis Ag 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
CA3058492A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
CN106543416A (zh) * 2016-10-21 2017-03-29 新疆大学 含嘧啶的聚合物在dmf溶液中检测硫酸浓度方面的应用
PT3579874T (pt) 2017-02-10 2021-10-07 Novartis Ag 1-(4-amino-5-bromo-6-(1h-pirazol-1-il)pirimidin-2-il)-1hpirazol- 4-ol e sua utilização no tratamento de cancro
JOP20190279A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CN107286146B (zh) * 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3755333A4 (en) 2018-02-16 2021-11-17 Arcus Biosciences, Inc. DOSAGE WITH AZOLOPYRIMIDINE COMPOUND
BR122022000386B1 (pt) 2018-03-14 2022-09-27 Surface Oncology, Inc Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
KR20250151605A (ko) 2018-06-01 2025-10-21 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
CN118834214A (zh) 2018-06-04 2024-10-25 爱克思科技有限公司 作为腺苷受体拮抗剂的吡唑并嘧啶化合物
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020011245A1 (zh) * 2018-07-13 2020-01-16 江苏恒瑞医药股份有限公司 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
JP7641894B2 (ja) * 2018-09-27 2025-03-07 アイテオ ベルギウム エスエー がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ
BE1026612B1 (fr) 2018-09-27 2020-07-02 Iteos Therapeutics S A Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202124444A (zh) 2019-09-16 2021-07-01 美商表面腫瘤學公司 抗ｃｄ３９抗體組合物及方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
AU2020353672A1 (en) 2019-09-25 2022-03-31 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
CN115996927A (zh) 2020-02-26 2023-04-21 Iteos比利时公司 作为ENT抑制剂用于治疗癌症的嘧啶并[5,4-d]嘧啶衍生物及其与腺苷受体拮抗剂的组合
CN113748110B (zh) * 2020-03-16 2024-05-14 上海海雁医药科技有限公司 取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途
CN113429410B (zh) * 2020-03-23 2022-10-04 上海海雁医药科技有限公司 多杂环取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途
JP7651590B2 (ja) * 2020-03-27 2025-03-26 ドン－ア エスティ カンパニー リミテッド アミノピリミジン誘導体およびアリール炭化水素受容体モジュレーターとしてのその使用
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
JP7784041B2 (ja) 2020-04-07 2025-12-11 アイテオ ベルギウム エスエー がんの治療のためのｅｎｔ阻害剤としての大環状ジアミン誘導体、及びそれとアデノシン受容体拮抗薬との組合せ
CN111362939B (zh) * 2020-04-26 2021-08-03 山东梅奥华卫科技有限公司 一种帕布昔利布母核结构化合物的制备方法
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
EP4294948A1 (en) 2021-02-17 2023-12-27 iTeos Belgium SA Compounds, compositions and methods of treatment thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023040863A1 (zh) * 2021-09-15 2023-03-23 上海海雁医药科技有限公司 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用
WO2024134541A1 (en) 2022-12-20 2024-06-27 iTeos Belgium SA Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers
TW202523332A (zh) 2023-11-14 2025-06-16 比利時商艾托斯比利時公司 Ｅｎｔ１抑制劑與檢查點抑制劑組合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2315736A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
NZ516260A (en) 1999-07-02 2004-08-27 Eisai Co Ltd Fused imidazole compounds and remedies for diabetes mellitus
KR100521735B1 (ko) * 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
EP1438053B1 (de) * 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI330183B (me) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
CA2551944A1 (en) * 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
WO2008070661A1 (en) * 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
WO2008116185A2 (en) * 2007-03-21 2008-09-25 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
WO2009032694A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis

Also Published As

Publication number Publication date
ES2365960B1 (es) 2012-06-04
CN102892761B (zh) 2015-02-04
WO2011121418A1 (en) 2011-10-06
WO2011121418A9 (en) 2012-04-05
PT2552909E (pt) 2015-04-23
EA021565B1 (ru) 2015-07-30
SI2552909T1 (sl) 2015-06-30
KR101441781B1 (ko) 2014-09-17
ZA201207259B (en) 2013-09-25
SMT201500097B (it) 2015-07-09
EA201201343A1 (ru) 2013-03-29
US20130053308A1 (en) 2013-02-28
AU2011234144B2 (en) 2014-04-24
DK2552909T3 (en) 2015-04-13
BR112012024870B1 (pt) 2020-11-17
MX2012011240A (es) 2012-11-30
ES2534227T3 (es) 2015-04-20
US8796284B2 (en) 2014-08-05
RS53939B1 (sr) 2015-08-31
AU2011234144A1 (en) 2012-10-25
PL2552909T3 (pl) 2015-08-31
BR112012024870A2 (pt) 2016-06-14
ES2365960A1 (es) 2011-10-14
HRP20150366T1 (hr) 2015-05-22
JP2013523711A (ja) 2013-06-17
EP2552909A1 (en) 2013-02-06
KR20130028732A (ko) 2013-03-19
JP5725383B2 (ja) 2015-05-27
CA2795009A1 (en) 2011-10-06
CY1116328T1 (el) 2017-02-08
CA2795009C (en) 2016-06-21
CN102892761A (zh) 2013-01-23
EP2552909B1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
ME02100B (me) Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora
US20230116233A1 (en) Compounds And Compositions As Protein Kinase Inhibitors
Akhtar et al. Recent progress of benzimidazole hybrids for anticancer potential
Satoh et al. Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino) pyrimidin-4-yl]-1, 3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist
CN101379060B (zh) 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
AU2015279377B2 (en) Indolin-2-one or pyrrolo-pyridin-2-one derivatives
JP2011520915A5 (me)
HUE034979T2 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
JP2004538260A (ja) 抗癌剤としてのサイクリン依存性キナーゼ阻害剤
CA2851082A1 (en) 1,3-substituted azetidine pde10 inhibitors
RU2415853C2 (ru) Бензимидазолы, применимые в качестве ингибиторов протеинкиназ
CN102573480B (zh) 三嗪衍生物及其治疗应用
EP1833820A1 (en) Selective inhibitors of erk protein kinase and uses therof
Nemeth et al. Novel, selective CDK9 inhibitors for the treatment of HIV infection
Narasimhachar et al. Development of novel pyrimidine-thio-triazoles targeting EGFR in breast Cancer cells via one-pot copper-catalyzed 1, 3-dipolar cycloaddition
ME02551B (me) Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde- 10)
JP2016505059A5 (me)
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
AU2005203919A1 (en) Selective kinase inhibitors
HK1191936B (en) Compounds and compositions as protein kinase inhibitors